Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,395 matching trials from the live ClinicalTrials.gov search.
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 48 more
Conditions
Arthritis, Psoriatic
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Encinitas, California • La Jolla, California • San Diego, California + 23 more
Conditions
Leukemia, Lymphoma
Interventions
lumiliximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Interventions
human Mesenchymal Stem Cells
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Terminated Phase 2 Interventional Results available

Gemcitabine and CT-011 for Resected Pancreatic Cancer

NCT01313416
Conditions
Pancreatic Neoplasms, Cancer of the Pancreas, Neoplasms Pancreatic, Pancreatic Cancer, Pancreas Cancer
Interventions
CT-011, Gemcitabine
Biological · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Lymphoma
Interventions
rituximab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
rhIL-15, Obinutuzumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional Results available

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

NCT05275998
Conditions
HIV-1-infection
Interventions
TMB-365/TMB-380
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more
Conditions
Cancer, Solid Tumor, Solid Tumor, Adult
Interventions
MNPR-101-DFO*-89Zr
Diagnostic Test
Lead sponsor
Monopar Therapeutics
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kidney Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neonatal Staphylococcal Sepsis
Interventions
Pagibaximab (formerly BSYX-A110)
Drug
Lead sponsor
Biosynexus Incorporated
Industry
Eligibility
3 Days to 7 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neoplasm
Interventions
Isatuximab SAR650984, Atezolizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Santa Monica, California • Boston, Massachusetts • Houston, Texas
Recruiting Phase 4 Interventional Accepts healthy volunteers

Safety of RSV Preventive Monoclonal Antibody

NCT07158814
Conditions
Fever, Adverse Event Following Immunisation
Interventions
Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Weeks to 30 Weeks
Enrollment
524 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Conditions
Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma
Interventions
rituximab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
29
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 25 more
Conditions
Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
American ginseng, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
326
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
Conditions
Pancreatic Carcinoma, Tumors That Express CA 19-9
Interventions
MVT-1075, MVT-5873
Drug
Lead sponsor
BioNTech Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • New York, New York
Conditions
HIV Antibodies
Interventions
VRC-HIVMAB091-00-AB, rHuPH20
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lung Cancer
Interventions
Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lupus
Interventions
MEDI-545
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
19
States / cities
Anniston, Alabama • Los Angeles, California • Clearwater, Florida + 14 more
Terminated Phase 2 Interventional Results available

HD Melphalan and SCT in Patients With IGDD or LCDD

NCT00681044
Conditions
Multiple Myeloma
Interventions
filgrastim, melphalan, Stem Cell Infusion
Biological · Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Advanced Cancer
Interventions
Bevacizumab, Sorafenib, Erlotinib, Trastuzumab, Lapatinib, Sunitinib, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neuroblastoma
Interventions
3F8 Monoclonal Antibody Combined with Interleukin-2
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
13 Months and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Stanford, California
Conditions
Multiple Myeloma
Interventions
SGN-40 (anti-huCD40 mAb)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
West Hollywood, California • Denver, Colorado • Boston, Massachusetts + 2 more